Kalbe Farma Tbk PT
IDX:KLBF
Kalbe Farma Tbk PT
Long-Term Debt
Kalbe Farma Tbk PT
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kalbe Farma Tbk PT
IDX:KLBF
|
Long-Term Debt
Rp221.6B
|
CAGR 3-Years
-25%
|
CAGR 5-Years
-19%
|
CAGR 10-Years
17%
|
|
|
T
|
Tempo Scan Pacific Tbk PT
IDX:TSPC
|
Long-Term Debt
Rp59B
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-22%
|
CAGR 10-Years
28%
|
|
|
Darya-Varia Laboratoria Tbk PT
IDX:DVLA
|
Long-Term Debt
Rp709.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Soho Global Health Tbk PT
IDX:SOHO
|
Long-Term Debt
Rp6.7B
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Pyridam Farma Tbk PT
IDX:PYFA
|
Long-Term Debt
Rp3.2T
|
CAGR 3-Years
106%
|
CAGR 5-Years
250%
|
CAGR 10-Years
76%
|
|
|
Kimia Farma Tbk PT
IDX:KAEF
|
Long-Term Debt
Rp2.4T
|
CAGR 3-Years
-7%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
128%
|
|
Kalbe Farma Tbk PT
Glance View
Kalbe Farma Tbk PT is a renowned pharmaceutical powerhouse rooted in Indonesia, rooted in a rich history that traces back to 1966. The company has evolved from a humble startup into a multifaceted entity with a robust portfolio, making it a vital player in the health and wellness sector across Southeast Asia. The company operates across four main business divisions: prescription pharmaceuticals, consumer health products, nutritionals, and distribution & logistics. By strategically linking these divisions, Kalbe Farma masterfully balances scientific innovation with market accessibility, ensuring a wide reach and varied product offering. This diversification not only broadens its revenue streams but also mitigates risk, securing its foothold in the competitive pharmaceutical landscape. At the core of Kalbe Farma’s business model lies a commitment to research and development, which fuels its cutting-edge product innovations and enhances its competitive edge. The company dedicates substantial resources to developing new medicines and health products, constantly seeking to address emerging health concerns. Moreover, its extensive distribution network fortifies its market presence, comprising a domestic distribution arm that penetrates even the farthest reaches of the Indonesian archipelago. This network ensures that Kalbe's products are widely available, amplifying their market penetration and revenue. Additionally, Kalbe embraces partnerships and collaborations to enhance its research capabilities and expand its product offerings, fostering an ecosystem where innovation and accessibility coexist harmoniously, thereby empowering its bottom line.
See Also
What is Kalbe Farma Tbk PT's Long-Term Debt?
Long-Term Debt
221.6B
IDR
Based on the financial report for Dec 31, 2024, Kalbe Farma Tbk PT's Long-Term Debt amounts to 221.6B IDR.
What is Kalbe Farma Tbk PT's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
17%
Over the last year, the Long-Term Debt growth was -31%. The average annual Long-Term Debt growth rates for Kalbe Farma Tbk PT have been -25% over the past three years , -19% over the past five years , and 17% over the past ten years .
You don't have any saved screeners yet